Cellular Goods claims that lab-made cannabinoids can help improve uneven skin tone as a result of factors including ageing, sun exposure and hormonal changes during pregnancy.
The UK-based wellness company Cellular Goods has submitted its first patent application for the use of cannabinoids in skin brightening products. The patent application comes after a series of research projects conducted by the company which found that cannabigerol (CBG) can improve the effectiveness of traditional skin brightening products.
Internal and external factors like hormonal changes during pregnancy and exposure to the sun can cause skin conditions such as melasma and hyperpigmentation that can make the skin tone change and become uneven. There are already a number of products within the beauty and cosmetics industry that claim to produce a brighter and more even skin tone.
Most products in the skin brightening market rely primarily on active ingredients such as Vitamin C, exfoliating acids and hydroquinones that, although effective in tackling melasma and hyperpigmentation, can cause skin irritation and sensitivity.
Cellular goods said there is a need for new ingredients that are as effective as those found in traditional skin brightening products without the uncomfortable side effects.
In an effort to find a suitable alternative, Cellular Goods conducted scientific research to assess the potential of cannabinoids as skin brightening ingredients. The series of research, which involved in-vitro human tissue models, found that lab-made cannabinoids, namely CBG, can improve the efficacy of certain active ingredients found in existing skin brightening products.
“From having skin brightening properties through to helping prevent the signs of ageing caused by UV light exposure and inflammation, cannabinoids have a number of skincare benefits that we are only just starting to understand,” Anna Chokina, CEO of Cellular Goods, said. “The filing of this patent based on our own research is part of our efforts to help unveil the benefits of cannabinoids, as well as to develop science-backed innovations that can improve people’s wellness.”
Cellular Goods has incorporated the research findings into its patent application, ‘Dermal Composition Comprising Cannabinoid and Derivatives Thereof’, filed on 26 April 2022 with the UK Intellectual Property Office. The company said the patent application will form part of a wider patent portfolio driven by Cellular Goods’ research into the wellness benefits of lab-made cannabinoids.
The company produces a range of skincare products including its ‘Rejuvenating Cannabinoid Face Serum’, the UK’s first CBG-based serum to prevent the signs of ageing caused by UV light exposure and inflammation.
“This work builds on our existing research involving lab-made cannabinoids, including the publication of a white paper on the potential benefits that cannabinoids can have for the skin by preventing the signs of ageing caused by UV exposure and inflammation,” said Alexia Blake, Head of Research and Product Development at Cellular Goods. “We are committed to continuing to develop research that will help us better understand the unique benefits of cannabinoids and how to effectively leverage these benefits across our product offerings.”
